A South Dakota man who says he must drive 70 miles round trip to fill his prescriptions is now pressing his antitrust case before the Eighth Circuit, arguing that powerful pharmacy benefit managers have squeezed independent pharmacies out of rural communities and left patients like him with fewer and fewer options.
The case, brought by plaintiff Dakotah Kirk against major pharmacy benefit managers (PBMs), centers on a claim that these corporate middlemen between insurers and pharmacies have used their market dominance to steer patients away from independent drugstores and toward PBM-owned pharmacy chains. Kirk alleges this practice has driven rural pharmacies out of business, forcing him and others in sparsely populated areas to travel long distances for basic medication access.
Pharmacy benefit managers negotiate drug prices between pharmaceutical manufacturers, insurance companies, and pharmacies. Three major PBMs control roughly 80 percent of the U.S. market: CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group). Kirk's lawsuit targets these firms and their parent companies, alleging they violated federal antitrust law by leveraging their dominance to favor their own affiliated pharmacies at the expense of independent competitors.
Kirk claims the PBMs set reimbursement rates so low that independent pharmacies cannot cover their costs, while simultaneously offering better terms to pharmacies the PBMs themselves own. The result, his attorneys argue, is a market rigged against small operators. When those independents close, patients in rural areas lose access to nearby prescription services.
As Courthouse News Service reported, Kirk told the court he must travel approximately 70 miles to reach a pharmacy that will fill his prescriptions, a burden he attributes directly to the closure of closer independent pharmacies that could not survive under PBM reimbursement structures.
A federal district court dismissed Kirk's claims before trial. The lower court found that Kirk had not sufficiently alleged antitrust injury or established standing to bring his claims. The judge concluded that the complaint did not draw a tight enough line between the PBMs' conduct and the specific harm Kirk experienced, namely the loss of his nearby pharmacy and the resulting 70-mile drive.
Kirk's legal team challenged that reasoning on appeal. They argued the district court applied too strict a standard at the pleading stage, where a plaintiff need only state a plausible claim, not prove it outright. The question before the Eighth Circuit is whether Kirk's allegations, taken as true for purposes of the appeal, state a viable antitrust case under the Sherman Act and related federal competition statutes.
During oral arguments before the Eighth Circuit panel, judges pressed both sides on the core antitrust questions. Kirk's attorneys argued that the PBMs' vertical integration, owning both the benefit management operation and the retail pharmacies, created inherent conflicts of interest. They contended the PBMs exploited that structure to eliminate competition.
Attorneys for the PBMs pushed back. They argued that low reimbursement rates alone do not constitute anticompetitive conduct and that independent pharmacy closures reflect broader market forces, not illegal behavior. The defense maintained that Kirk's theory of harm was too speculative to survive even the pleading stage.
The judges appeared interested in the mechanics of how PBM reimbursement rates are set and whether the spread between what PBMs pay independent pharmacies and what they pay their own affiliated pharmacies could amount to self-dealing that harms competition. No ruling was issued from the bench. The panel took the case under advisement.
Kirk's case taps into a growing national frustration over rural pharmacy closures. Across the Great Plains and other sparsely populated regions, independent pharmacies have shuttered at an accelerating pace over the past decade. Industry groups representing independent pharmacists have blamed PBM reimbursement practices as a primary driver, arguing that the rates offered often fall below the pharmacy's actual cost to acquire and dispense the medication.
For patients in these areas, losing a local pharmacy does not simply mean an inconvenience. It can mean delayed access to critical medications, including insulin, blood pressure drugs, and antibiotics. Elderly patients and those without reliable transportation face the steepest burden. Kirk's 70-mile drive illustrates the real-world cost of market consolidation in the pharmacy sector.
The case also intersects with a broader bipartisan push to regulate PBMs more aggressively. Lawmakers in multiple states have introduced or passed legislation aimed at increasing transparency in PBM pricing and restricting the practice of steering patients toward PBM-owned pharmacies. At the federal level, the Federal Trade Commission released a report in 2024 criticizing PBM business practices and their impact on drug pricing.
Kirk's claims rest primarily on the Sherman Antitrust Act, the foundational federal law prohibiting monopolistic conduct and conspiracies to restrain trade. His attorneys argue the PBMs engaged in both: using their dominant market position to crush independent competitors and coordinating practices across the industry that had the effect of eliminating competition.
The legal standard Kirk must meet at this stage is relatively modest. Under Supreme Court precedent established in cases like Bell Atlantic Corp. v. Twombly and Ashcroft v. Iqbal, a plaintiff must plead facts that make the alleged antitrust violation plausible, not merely possible. The district court found Kirk fell short. The Eighth Circuit must now decide whether that was the correct call.
One key issue is whether Kirk qualifies as a proper antitrust plaintiff. Federal courts have historically required that the person bringing the suit suffered a direct injury from the alleged anticompetitive conduct, not an injury that passed through several intermediaries before reaching the plaintiff. The PBMs argue Kirk's harm is too attenuated. Kirk's team counters that he is exactly the type of consumer Congress intended to protect when it enacted antitrust laws.
If the Eighth Circuit reverses the dismissal and allows Kirk's case to proceed, it could open the door to a wave of similar lawsuits from consumers and independent pharmacies across the country. A ruling that PBM self-dealing and differential reimbursement rates can state a plausible antitrust claim would give plaintiffs a template for challenging the industry's business model in court.
If the panel affirms the dismissal, it would signal that federal antitrust law, at least in the Eighth Circuit, offers limited recourse for consumers harmed by PBM consolidation. That outcome would likely push the fight further into the legislative arena, where state and federal lawmakers are already debating PBM reform bills.
The case is being watched closely by pharmacy trade associations, consumer advocacy groups, and the PBM industry itself. The Eighth Circuit's decision could arrive within the coming months, though the court has set no public deadline for its ruling.
Several critical questions remain unresolved. Authorities and courts have not publicly established whether PBM reimbursement rates to independent pharmacies are systematically below acquisition cost, or whether the differential between independent and affiliated pharmacy reimbursements is large enough to constitute anticompetitive self-dealing under federal law.
Investigators will also need to determine whether the three dominant PBMs acted independently or in coordination when setting reimbursement structures. Kirk's complaint alleges parallel conduct, but parallel behavior alone does not prove a conspiracy under antitrust law. The distinction between independent business decisions and an illegal agreement is one the courts will need to examine if the case moves forward.
The Eighth Circuit has not indicated when it will rule. Both sides have filed their briefs, and the case now rests with the panel.
When a man has to burn a tank of gas just to pick up his blood pressure medication, something in the system has gone sideways. Whether the courts or Congress fix it first may depend on what the Eighth Circuit decides to do next.
